White Paper: CMO’s Dilemma: What Will Be the “New Normal”?
It remains no secret that Pharma marketing is in a state of flux, precipitated by the COVID-19 pandemic. Virtual Channels, Promotion and Messaging are the Only Option Now. With this as a backdrop, the graphic below serves as an introductory glimpse into the latest edition of SRI’s Virtual Viewpoint: CMO’s Dilemma: What Will Be the “New Normal”, a consultative perspective from our senior team on the future of pharma sales and promotion in the current era.
Pharma companies have relied on in-person communications with HCPs to educate them about new clinical research, indications, and other drug specific information. However, this traditional model is now rapidly adapting to the “New Normal”, with virtual modes and models of communication with HCPs and their practices by Pharma Sales and Marketing teams rising to the forefront.
Ultimately, the resilience and success of pharma companies will be driven by the way they plan and execute their sales strategy by maneuvering through and settling into this “New Normal”. In this whitepaper, SRI provides a glance into three potential, viable pathways in this new era: Back to The Future, Old is Gold and Melting Pot. As with any edition of our Virtual Viewpoint, our lens and communication may offer a distinct, pioneering approach, or simply provide a succinct validation of what your brand is deeply thinking, exploring or already executing. In all cases, we appreciate your interest in SRI, welcome your feedback, and look forward to receiving your creative suggestions for future Virtual Viewpoint topics.